V2receptor antagonism with tolvaptan in heart failure
Authors:
- Lisa C Costello-BoerrigterLCLisa C Costello-Boerrigter
- Guido BoerrigterGBGuido Boerrigter
- John C BurnettJBJohn C Burnett
- 9 October 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 16 (10) , 1639-1647
Abstract
The prevalence and incidence of congestive heart failure continues to increase. The two hallmarks of this syndrome, sodium and water retention, are frequently a therapeutic challenge. Most conventional diuretics act primarily as saluretics by inhibiting renal tubular electrolyte reabsorption, which, due to osmotic pressure, promotes excretion of isotonic fluid. The peptide hormone arginine vasopressin vasoconstricts at the V1A receptor and promotes water reabsorption via the V2 receptor in the renal collecting duct by inserting aquaporin-2 water channels into the luminal membrane. Tolvaptan, the first orally available non-peptide V2 receptor antagonist, acts as a potent aquaretic. In this paper, the authors review the pharmacology of tolvaptan and discuss the results of the initial clinical trials with this potent new drug.Keywords
This publication has 27 references indexed in Scilit:
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status TrialsJAMA, 2007
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007
- Heart Disease and Stroke Statistics—2007 UpdateCirculation, 2007
- Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic DysfunctionCirculation, 2006
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart FailureCirculation, 2006
- Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart FailureA Randomized Controlled TrialJAMA, 2004
- Vasopressin V 2 -Receptor Blockade With Tolvaptan in Patients With Chronic Heart FailureCirculation, 2003
- Renal Function, Neurohormonal Activation, and Survival in Patients With Chronic Heart FailureCirculation, 2000
- The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunctionJACC, 2000
- Diuretics and Risk of Arrhythmic Death in Patients With Left Ventricular DysfunctionCirculation, 1999